Art

J-GLOBAL ID：201602252298847943   Reference number：16A0642398

Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases

Niemann-Pick C1様1阻害剤,エゼチミブの長期投与は肝胆疾患を伴う脂質異常症患者における胆汁結石形成を悪化させない

Author (6)： Kishikawa Nobusuke (Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan) ,  Kanno Keishi (Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan) ,  Sugiyama Akiko (Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan) ,  Yokobayashi Kenichi (Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan) ,  Mizooka Masafumi (Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan) ,  Tazuma Susumu (Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. [e-mail])
Material： Journal of Hepato-Biliary-Pancreatic Sciences  (J Hepato Biliary Pancreat Sci)
Volume： 23  Issue： 2  Page： 125-131  Publication year： 2016 
JST Material Number： W2410A  ISSN： 1868-6974  Document type： Article
Article type： 原著論文  Country of issue： Australia (AUS)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： Niemann-Pick C1 like 1 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0642398&from=J-GLOBAL&jstjournalNo=W2410A") }}

Author keywords (5)： Bile lithogenicity ,  Cholecystectomy ,  Ezetimibe ,  Niemann-Pick C1-like 1 ,  Ursodeoxycholic acid

JST classification (2)： Treatment for metabolic diseases,nutritional diseases.  (GD05030F) ,  Digestive system diseases  (GH03000W)

Substance index (2)： Ursodeoxycholic Acid ,  Ezetimibe

Reference (20)：

• Hyogo H, Tazuma S, Cohen DE. Cholesterol gallstones. Curr Opin Gastroenterol. 2002;18:366-71.
• Wang HH, Portincasa P, de Bari O, Liu KJ, Garruti G, Neuschwander-Tetri BA, et al. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur J Clin Invest. 2013;43:413-26.
• Caroli-Bosc FX, Le Gall P, Pugliese P, Delabre B, Caroli-Bosc C, Demarquay JF, et al. General Practitioners' Group of Vidauban. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci. 2001;46:540-4.
• Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambón D, Ros E, et al. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol. 2004;59:855-61.
• Tazuma S, Takizawa I, Kunita T, Mizuno T, Watanabe T, Teramen K, et al. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Metabolism. 1995;44:1410-2.

Terms in the title (10)： C1 ,  阻害剤 ,  エゼチミブ ,  長期投与 ,  疾患 ,  脂質異常症 ,  患者 ,  胆汁 ,  結石 ,  悪化